心肌内注射骨髓干细胞联合血运重建术的I期试验
这项I期试验评估了自体骨髓基质/干细胞(BMSC)经心肌内直接注射联合经心肌血运重建(TMR)或冠状动脉旁路移植术(CABG)的安全性和可行性。共14例缺血性心肌病伴左室射血分数降低的患者接受治疗(TMR+BMSC 10例,CABG+BMSC 4例),未出现显著并发症,1年时细胞治疗区域收缩功能改善且心绞痛评分降低。
要点
- 自体BMSC联合TMR或CABG心肌内注射技术上可行且安全。
- 1年时心绞痛评分显著降低,生活质量提升。
核心结论
- 自体BMSC心肌内注射联合TMR或CABG技术可行且可安全实施。
- 初步结果显示治疗后1年心脏功能和生活质量改善。
研究设计与样本
- I期试验纳入缺血性心脏病伴左室射血分数降低的成人患者,拟行TMR或CABG。
- 自体BMSC术前扩增3周,血运重建完成后直接注射至缺血心肌。
- 共14例患者接受同步BMSC与外科血运重建治疗(TMR+BMSC 10例;CABG+BMSC 4例)。
主要发现
- BMSC成功扩增,操作未导致显著并发症。
- 治疗后1年心绞痛评分大幅降低(TMR+BMSC:1.3±1.2;CABG+BMSC:1.0±1.4),生活质量提升。
关键数值与推荐
- 1年心绞痛评分:TMR+BMSC组1.3±1.2,CABG+BMSC组1.0±1.4。
临床怎么用
- 对于缺血性心肌病伴左室功能降低需血运重建者,可考虑联合自体BMSC心肌内注射。
- 该疗法处于I期试验阶段,需进一步验证疗效。
局限性
- I期试验样本量小(共14例),CABG+BMSC亚组仅4例。
- 缺乏对照组,初步结果需更大规模随机试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone marrow stromal or stem cells (BMSCs) remain a promising potential therapy for ischemic cardiomyopathy. The primary objective of this study was to evaluate the safety and feasibility of direct intramyocardial injection of autologous BMSCs in patients undergoing transmyocardial revascularization (TMR) or coronary artery bypass graft surgery (CABG). METHODS: A phase I trial was conducted on adult patients who had ischemic heart disease with depressed left ventricular ejection fraction and who were scheduled to undergo TMR or CABG. Autologous BMSCs were expanded for 3 weeks before the scheduled surgery. After completion of surgical revascularization, BMSCs were directly injected into ischemic myocardium. Safety and feasibility of therapy were assessed. Cardiac functional status and changes in quality of life were evaluated at 1 year. RESULTS: A total of 14 patients underwent simultaneous BMSC and surgical revascularization therapy (TMR+BMSCs = 10; CABG+BMSCs = 4). BMSCs were successfully expanded, and no significant complications occurred as a result of the procedure. Regional contractility in the cell-treated areas demonstrated improvement at 12 months compared with baseline (TMR+BMSCs Δ strain: -4.6% ± 2.1%; P = .02; CABG+MSCs Δ strain: -4.2% ± 6.0%; P = .30). Quality of life was enhanced, with substantial reduction in angina scores at 1 year after treatment (TMR+BMSCs: 1.3 ± 1.2; CABG+MSCs: 1.0 ± 1.4). CONCLUSIONS: In this phase I trial, direct intramyocardial injection of autologous BMSCs in conjunction with TMR or CABG was technically feasible and could be performed safely. Preliminary results demonstrate improved cardiac function and quality of life in patients at 1 year after treatment.
引用
- Chan JL, Miller JG, Zhou Y, et al. Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical Revascularization. Ann Thorac Surg. 2019. PMID: 31526779. doi:10.1016/j.athoracsur.2019.07.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。